Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Medtronic
McKesson
Mallinckrodt
AstraZeneca

Last Updated: January 19, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Bavituximab


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Bavituximab?

Bavituximab is an investigational drug.

There have been 26 clinical trials for Bavituximab. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2013.

The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Breast Neoplasms, and Carcinoma. The leading clinical trial sponsors are Peregrine Pharmaceuticals, University of Texas Southwestern Medical Center, and National Comprehensive Cancer Network.

There are thirty-seven US patents protecting this investigational drug and eight hundred and sixty-six international patents.

Recent Clinical Trials for Bavituximab
TitleSponsorPhase
1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and NeckUniversity of Maryland, BaltimorePhase 2
An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer PatientsMerck Sharp & Dohme Corp.Phase 2
An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer PatientsOncologie Inc.Phase 2

See all Bavituximab clinical trials

Clinical Trial Summary for Bavituximab

Top disease conditions for Bavituximab
Top clinical trial sponsors for Bavituximab

See all Bavituximab clinical trials

US Patents for Bavituximab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Bavituximab ⤷  Try it Free Multispecific constructs AbbVie Stemcentrx LLC (North Chicago, IL) ⤷  Try it Free
Bavituximab ⤷  Try it Free .beta.-glucan methods and compositions that affect the tumor microenvironment BIOTHERA, INC. (Eagan, MN) ⤷  Try it Free
Bavituximab ⤷  Try it Free Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE) ⤷  Try it Free
Bavituximab ⤷  Try it Free Method of treating pancreatic cancer ChemoCentryx, Inc. (Mountain View, CA) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Bavituximab

Drugname Country Document Number Estimated Expiration Related US Patent
Bavituximab Canada CA2900764 2033-02-08 ⤷  Try it Free
Bavituximab European Patent Office EP2954056 2033-02-08 ⤷  Try it Free
Bavituximab Hong Kong HK1218930 2033-02-08 ⤷  Try it Free
Bavituximab Japan JP2016509014 2033-02-08 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Medtronic
McKesson
Mallinckrodt
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.